Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Angiogenesis inhibition in renal cell cancer

Angiogenesis inhibition in renal cell cancer Several targets have been identified for the therapy of metastatic renal cell carcinoma (RCC). The recognition of hypoxia-inducible factor-α signaling in the pathogenesis of clear-cell RCC has led to widespread study of angiogenesis inhibitors. Understanding this molecular pathogenesis of RCC led to a rapid evolvement of new systemic therapies, with seven targeted therapies approved and several more agents in late-stage clinical development. Due to the results of the currently used targeted therapies, the progression-free survival could be prolonged and the overall survival in sequential therapy can reach up to 40 months. The development of validated guidelines for sequential treatment or combination of targeted therapy remains a current challenge. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Angiogenesis inhibition in renal cell cancer

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/angiogenesis-inhibition-in-renal-cell-cancer-05YstRDI7a
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0160-x
Publisher site
See Article on Publisher Site

Abstract

Several targets have been identified for the therapy of metastatic renal cell carcinoma (RCC). The recognition of hypoxia-inducible factor-α signaling in the pathogenesis of clear-cell RCC has led to widespread study of angiogenesis inhibitors. Understanding this molecular pathogenesis of RCC led to a rapid evolvement of new systemic therapies, with seven targeted therapies approved and several more agents in late-stage clinical development. Due to the results of the currently used targeted therapies, the progression-free survival could be prolonged and the overall survival in sequential therapy can reach up to 40 months. The development of validated guidelines for sequential treatment or combination of targeted therapy remains a current challenge.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jul 31, 2014

References

  • Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B
  • Molecular basis of the VHL hereditary cancer syndrome
    Kaelin, WG
  • Inhibition of HIF is necessary for tumor suppression by the von Hippel–Lindau protein
    Kondo, K
  • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
    Cho, D
  • Clinical significance of the determination of angiogenic factors
    Toi, M
  • Chemotherapy for advanced renal-cell carcinoma: 1983–1993
    Yagoda, A; Abi-Rached, B; Petrylak, D
  • Optimal management of metastatic renal cell carcinoma: an algorithm for treatment
    Bellmunt, J
  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Motzer, RJ
  • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Motzer, RJ
  • Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
    Escudier, B
  • Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Motzer, RJ
  • Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
    Escudier, B
  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Hudes, G
  • Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
    Poprach, A
  • Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients
    Herrmann, E
  • Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action
    Gonzalez Larriba, JL
  • Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, B
  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Motzer, RJ
  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Rini, BI
  • Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    Escudier, B
  • Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy
    Calvo, E; Grunwald, V; Bellmunt, J
  • A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
    Funakoshi, T; Lee, CH; Hsieh, JJ
  • Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma
    Bierer, S
  • Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger, M
  • Vaccination strategies in patients with renal cell carcinoma
    Asemissen, AM; Brossart, P